Tag Archives: 72M

Danish biotech looking for area of interest vaccine edge towards Pfizer snags €72M for pivotal research – Endfactors News

A biotech 12 years in the mak­ing has se­cured its largest fi­nanc­ing yet, and it has am­bi­tious plans for what the chief ex­ec­u­tive called a “David vs. Go­liath” ven­ture. Min­er­vaX, based out of Copen­hagen, put out word bright and ear­ly Thurs­day that it se­cured €72 mil­lion in new fund­ing via both eq­ui­ty fi­nanc­ing and a […]